Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,870.00 | |
50 mg | 10-14 weeks | $ 3,780.00 | |
100 mg | 10-14 weeks | $ 5,200.00 |
Description | HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. |
Targets&IC50 | genotypic HCV NS5A:3-47 pM |
In vitro | HCV-IN-7 (10 μM) has cytotoxicity of 14%, 22%, 36% in Huh7, HepG2 and HEK cells, respectively. ?HCV-IN-7 has a less complex central tricyclic core as novel and potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile.?HCV-IN-7 inhibits GT1b (IC50=12 pM), GT2a (IC50=5 pM), GT1a (IC50=27 pM), GT3a (IC50=47 pM), GT4a (IC50=3 pM), GT6a (IC50=28 pM). ?HCV-IN-7 (10 μM) has 12%, 42%, 12% inhibition for CYP2D6, CYP2C9, CYP3A4, respectively. |
In vivo | HCV-IN-7 (iv; 1 mg/kg) has a T1/2 of 4 hours, CL of 6 mL/min/kg, and a Vss of 2 L/kg for dog. ?HCV-IN-7 (po; 10 mg/kg) has a Cmax of 5 μM and an AUClast of 49 μM for dog.?HCV-IN-7 (iv; 1 mg/kg) has a T1/2 of 2 hours, CL of 11 mL/min/kg, and a Vss of 2 L/kg for rats. ?HCV-IN-7 (po; 10 mg/kg) has a Cmax of 1 μM and an AUClast of 6 μM for rats. |
Molecular Weight | 768.92 |
Formula | C40H48N8O6S |
CAS No. | 1449756-86-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HCV-IN-7 1449756-86-8 Others HCVIN7 HCV IN 7 inhibitor inhibit